Patents by Inventor Michael L. Gosselin

Michael L. Gosselin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10442851
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: October 15, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Rex Parker, Ray Camphausen, Jonathan Davis, David Fabrizio
  • Publication number: 20190300608
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
    Type: Application
    Filed: April 1, 2019
    Publication date: October 3, 2019
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Achal Pashine, Michael L. Gosselin, Aaron P. Yamniuk, Derek A. Holmes, Guodong Chen, Priyanka Apurva Madia
  • Publication number: 20190203248
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: January 10, 2019
    Publication date: July 4, 2019
    Inventors: Michael L. GOSSELIN, David FABRIZIO, Joanna F. SWAIN, Tracy MITCHELL, Ray CAMPHAUSEN, Sharon T. CLOAD, Eric FURFINE, Paul E. MORIN, Ranjan MUKHERJEE, Simeon I. TAYLOR
  • Patent number: 10221438
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: March 5, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Michael L. Gosselin, David Fabrizio, Joanna F. Swain, Tracy Mitchell, Ray Camphausen, Sharon T. Cload, Eric Furfine, Paul E. Morin, Ranjan Mukherjee, Simeon I. Taylor
  • Publication number: 20180258158
    Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: September 22, 2016
    Publication date: September 13, 2018
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Stanley Richard KRYSTEK, Jr., Tracy S. MITCHELL, Michael L. GOSSELIN, Dasa LIPOVSEK, Juhi JUNEJA
  • Publication number: 20170174748
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: March 19, 2015
    Publication date: June 22, 2017
    Inventors: Tracy S. MITCHELL, Michael L. GOSSELIN, Dasa LIPOVSEK, Rex PARKER, Ray CAMPHAUSEN, Jonathan DAVIS, David FABRIZIO
  • Publication number: 20170145464
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: November 29, 2016
    Publication date: May 25, 2017
    Inventors: Michael L. GOSSELIN, David FABRIZIO, Joanna F. SWAIN, Tracy MITCHELL, Ray CAMPHAUSEN, Sharon T. CLOAD, Eric FURFINE, Paul E. MORIN, Ranjan MUKHERJEE, Simeon I. TAYLOR
  • Patent number: 9540424
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: January 10, 2017
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Michael L. Gosselin, David Fabrizio, Joanna F. Swain, Tracy Mitchell, Ray Camphausen, Sharon T. Cload, Eric Furfine, Paul E. Morin, Ranjan Mukerjee, Simeon I. Taylor
  • Publication number: 20150152147
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: November 25, 2014
    Publication date: June 4, 2015
    Inventors: Michael L. GOSSELIN, David FABRIZIO, Joanna F. SWAIN, Tracy MITCHELL, Ray CAMPHAUSEN, Sharon T. CLOAD, Eric FURFINE, Paul E. MORIN, Ranjan MUKHERJEE, Simeon I. TAYLOR
  • Patent number: 8969289
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: May 2, 2011
    Date of Patent: March 3, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael L. Gosselin, David Fabrizio, Joanna F. Swain, Tracy Mitchell, Ray Camphausen, Sharon T. Cload, Eric Furfine, Paul E. Morin, Ranjan Mukherjee, Simeon I. Taylor
  • Publication number: 20110305663
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: May 2, 2011
    Publication date: December 15, 2011
    Applicant: Bristol-Myers Squibb Company
    Inventors: Michael L. Gosselin, David Fabrizio, Joanna F. Swain, Tracy Mitchell, Ray Camphausen, Sharon T. Cload, Eric Furfine, Paul E. Morin, Ranjan Mukherjee, Simeon I. Taylor
  • Patent number: 6057131
    Abstract: Provided are methods of making preparations of recombinant soluble Complement Receptor type 1 (sCR1) defined with respect to the distribution of sCR1 glycoforms and therapeutic methods using them. The preparations are suitable for treatment of allograft or xenograft rejection, diseases involving inflammation or inappropriate complement activation, and thrombotic or shock state conditions. Preferred methods employ sCR1 glycoforms that are sialylated, have a pI of .ltoreq.5.1, or have a sialic acid: mannose molar ratio of .gtoreq.0.25.
    Type: Grant
    Filed: November 5, 1998
    Date of Patent: May 2, 2000
    Assignee: Avant Immunotherapeutics, Inc.
    Inventors: Henry C. Marsh, Jr., Richard A. G. Smith, Chang-Jing Grace Yeh, John Lifter, Anne Mary Freeman, Michael L. Gosselin
  • Patent number: 5858969
    Abstract: Provided are therapeutic methods employing preparations of recombinant soluble Complement Receptor type 1 (sCR1) defined with respect to the distribution of sCR1 glycoforms. The methods are suitable for treatment of disease involving inflammation, inappropriate complement activation, and in thrombotic or shock state conditions. Preferred methods employ sCR1 glycoforms that are sialylated, have a pI of .ltoreq.5.1, or have a sialic acid:mannose molar ratio of .gtoreq.0.25.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 12, 1999
    Assignee: T Cell Sciences, Inc.
    Inventors: Henry C. Marsh, Jr., Richard A.G. Smith, Chang-Jing Grace Yeh, John Lifter, Anne Mary Freeman, Michael L. Gosselin
  • Patent number: 5456909
    Abstract: The present invention relates to novel glycoforms and preparations of the soluble complement receptor type 1 (sCR1), and their uses in the therapy of complement mediated diseases and disorders involving inflammation and inappropriate complement activation and in thrombotic or shock state conditions. The invention provides novel glycoforms and methods for producing, detecting, enriching and purifying such glycoforms. The invention further provides methods of specifically producing a glycoform by recombinant or chemical means. Preferred embodiments of the invention include sialylated glycoforms and glycoforms with a pI.ltoreq.5.1 determined by chromatofocusing or with a sialic acid to mannose molar ratio of >0.25. The glycoforms may be formulated alone in therapeutic compositions or in combination with thrombolytic agents.
    Type: Grant
    Filed: August 7, 1992
    Date of Patent: October 10, 1995
    Assignees: T Cell Sciences, Inc., SmithKline Beecham p.l.c.
    Inventors: Henry C. Marsh, Jr., Richard A. G. Smith, Chang-Jing G. Yeh, John Lifter, Anne M. Freeman, Michael L. Gosselin